Skip to main content
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences 5/2009

01.09.2009 | Original article

Nonfunctioning neuroendocrine pancreatic tumors: our experience and management

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

We present our experience in the treatment of nonfunctioning neuroendocrine pancreatic tumors (NFNPTs) to define the clinical and pathological characteristics and to suggest proper management.

Methods

The records of 17 patients with NFNPTs operated on between 1998 and 2008 were retrospectively reviewed, and all tumors were classified clinicopathologically as benign, uncertain, and malignant, based on the World Health Organization (WHO) classification of neuroendocrine tumors.

Results

There were four benign, six uncertain, and seven malignant NFNPTs. The most frequent symptoms were abdominal pain (five patients) and obstructive jaundice (one patient). Most of these symptomatic patients had malignant tumors. Mean tumor size of benign, uncertain, and malignant tumors were 1.0 ± 0.3, 3.2 ± 1.6, and 5.3 ± 2.4 cm, respectively. Metastatic lesions of malignant tumors were lymph node (six patients), liver (four patients), and adrenal gland (one patient). Six of seven patients with malignant tumors underwent curative rejection. There were recurrences in four of six patients with curatively rejected malignant tumors. Two patients underwent more rejection, three patients received systemic chemotherapy, and two patients underwent radiofrequency ablation and transcatheter arterial chemoembolization for liver metastases. Survival of patients with malignant tumors was significantly shorter than that of patients with benign and uncertain tumors. However, three patients with malignant tumors had long survival of more than 3 years, even with metastases or recurrences.

Conclusions

Aggressive surgical resection should be performed in patients with resectable NFNPTs, even with metastases. Even when a tumor was unresectable or there were recurrences, long-time palliation could be achieved by a multidisciplinary approach.
Literatur
1.
Zurück zum Zitat Moldow RE, Conelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677–86.PubMed Moldow RE, Conelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677–86.PubMed
2.
Zurück zum Zitat Kent RB, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981;193:185–90.PubMedCrossRef Kent RB, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981;193:185–90.PubMedCrossRef
3.
Zurück zum Zitat Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet tumors. Surgery. 1986;99:671–8.PubMed Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet tumors. Surgery. 1986;99:671–8.PubMed
4.
Zurück zum Zitat Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch. 1995;425:547–60.PubMedCrossRef Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch. 1995;425:547–60.PubMedCrossRef
5.
Zurück zum Zitat Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Prac. 1998;183:155–68. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Prac. 1998;183:155–68.
6.
Zurück zum Zitat DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of the endocrine organs. WHO classification of tumors. Lyon: IARC Press; 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of the endocrine organs. WHO classification of tumors. Lyon: IARC Press; 2004.
7.
Zurück zum Zitat La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–33.PubMed La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–33.PubMed
8.
Zurück zum Zitat Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993;114:1175–82.PubMed Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993;114:1175–82.PubMed
9.
Zurück zum Zitat Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, et al. Nonfunctional pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;98:2435–9.PubMedCrossRef Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, et al. Nonfunctional pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;98:2435–9.PubMedCrossRef
10.
Zurück zum Zitat Nakao A. Pancreatic head resection with segmental duodenectomy and preservation of the gastroduodenal artery. Hepatogastroenterology. 1998;45:533–5.PubMed Nakao A. Pancreatic head resection with segmental duodenectomy and preservation of the gastroduodenal artery. Hepatogastroenterology. 1998;45:533–5.PubMed
11.
Zurück zum Zitat Procacci C, Carbognin G, Accordini S, Biasiutti C, Bicego E, Romano L, et al. Nonfunctional endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol. 2001;11:1175–83.PubMedCrossRef Procacci C, Carbognin G, Accordini S, Biasiutti C, Bicego E, Romano L, et al. Nonfunctional endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol. 2001;11:1175–83.PubMedCrossRef
12.
Zurück zum Zitat Sugiyama M, Abe N, Izumisato Y, Yamaguchi Y, Yamato T, Tokuhara M, et al. Differential diagnosis of benign versus malignant nonfunctioning islet cell tumors of the pancreas: the roles of EUS and ERCP. Gastrointest Endosc. 2002;55:115–9.PubMedCrossRef Sugiyama M, Abe N, Izumisato Y, Yamaguchi Y, Yamato T, Tokuhara M, et al. Differential diagnosis of benign versus malignant nonfunctioning islet cell tumors of the pancreas: the roles of EUS and ERCP. Gastrointest Endosc. 2002;55:115–9.PubMedCrossRef
13.
Zurück zum Zitat Klöppel G, Schroder S, Heitz PU. Histopathology and immunopathology of the pancreatic endocrine tumors. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas. Recent advances in research and management. Basel: Karger; 1995. p. 99–120. Klöppel G, Schroder S, Heitz PU. Histopathology and immunopathology of the pancreatic endocrine tumors. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas. Recent advances in research and management. Basel: Karger; 1995. p. 99–120.
14.
Zurück zum Zitat Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–7.PubMedCrossRef Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–7.PubMedCrossRef
15.
Zurück zum Zitat Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.PubMedCrossRef Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.PubMedCrossRef
16.
Zurück zum Zitat Bartch DK, Langer P, Wild A, Schilling T, Celik I, Rothmund M, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000;128:958–66.CrossRef Bartch DK, Langer P, Wild A, Schilling T, Celik I, Rothmund M, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000;128:958–66.CrossRef
17.
Zurück zum Zitat Solorzano CC, Lee JE, Pisters PWT, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.PubMedCrossRef Solorzano CC, Lee JE, Pisters PWT, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.PubMedCrossRef
18.
Zurück zum Zitat Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–85.PubMedCrossRef Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–85.PubMedCrossRef
19.
Zurück zum Zitat Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–65.PubMedCrossRef Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–65.PubMedCrossRef
20.
Zurück zum Zitat Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–82.PubMedCrossRef Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–82.PubMedCrossRef
21.
Zurück zum Zitat Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.PubMedCrossRef Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.PubMedCrossRef
22.
Zurück zum Zitat McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–6.PubMed McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–6.PubMed
23.
Zurück zum Zitat Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–4.PubMedCrossRef Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–4.PubMedCrossRef
24.
Zurück zum Zitat Ho AS, Picus J, Darcy MD, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188:1201–7.CrossRef Ho AS, Picus J, Darcy MD, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188:1201–7.CrossRef
25.
Zurück zum Zitat Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8–12.PubMedCrossRef Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8–12.PubMedCrossRef
26.
Zurück zum Zitat Moertel CG, Lefkopould M, Lipsitz S, Hahn RG. Streptozocin–doxorubicin, streptozocin–fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.PubMed Moertel CG, Lefkopould M, Lipsitz S, Hahn RG. Streptozocin–doxorubicin, streptozocin–fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.PubMed
27.
Zurück zum Zitat Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139–43.PubMedCrossRef Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139–43.PubMedCrossRef
28.
Zurück zum Zitat Arnold R, Rinke A, Schmidt Ch, Hofbauer L. Endocrine tumors of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol. 2005;19:649–56.PubMedCrossRef Arnold R, Rinke A, Schmidt Ch, Hofbauer L. Endocrine tumors of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol. 2005;19:649–56.PubMedCrossRef
29.
Zurück zum Zitat Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Bartolomeo M, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372–8.PubMedCrossRef Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Bartolomeo M, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372–8.PubMedCrossRef
30.
Zurück zum Zitat Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244–8.PubMedCrossRef Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244–8.PubMedCrossRef
31.
Zurück zum Zitat Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. ITMO Association. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer. 1996;77:402–8.PubMedCrossRef Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. ITMO Association. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer. 1996;77:402–8.PubMedCrossRef
32.
Zurück zum Zitat Fjällskog ML, Sundin A, Westlin JE, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35–42.PubMedCrossRef Fjällskog ML, Sundin A, Westlin JE, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35–42.PubMedCrossRef
Metadaten
Titel
Nonfunctioning neuroendocrine pancreatic tumors: our experience and management
Publikationsdatum
01.09.2009
Erschienen in
Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 5/2009
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-009-0099-1

Weitere Artikel der Ausgabe 5/2009

Journal of Hepato-Biliary-Pancreatic Sciences 5/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.